Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By in... https://annelis086rtu7.wikicommunication.com/user